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Induction of haem oxygenase-1 (HO-1) may provide an important protective effect for cells against oxidative stress. Here, we
investigated the mechanism of cytoprotection of HO-1 in solid tumour with a focus on the antiapoptotic activity of HO-1. Treatment
of rat hepatoma AH136B cells with the HO inhibitor zinc protoporphyrin IX (ZnPP IX) or tin protoporphyrin IX resulted in extensive
apoptotic changes of tumour cells both in vivo and in vitro. Caspase-3 activity of the ZnPP IX-treated hepatoma cells increased
significantly. Moreover, ZnPP IX-induced apoptosis was completely inhibited by simultaneous incubation with a specific caspase-3
inhibitor and was partially abrogated by bilirubin, a reaction product of HO. In vivo ZnPP IX treatment did not affect nitric oxide (NO)
production and tumour blood flow. Western blot analyses showed that HO-1 expression in AH136B cells was strongly upregulated
by NO donors, for example, S-nitroso-N-acetyl penicillamine and propylamine NONOate in vitro; conversely, it was remarkably
reduced in vivo by pharmacological blockade of NOS. We conclude that HO-1 may function in antiapoptotic defense of the tumour,
and thus it may have important protective and beneficial effects for tumour cells against oxidative stress induced by NO, which is
produced in excess during solid tumour growth in vivo.
British Journal of Cancer (2003) 88, 902–909. doi:10.1038/sj.bjc.6600830 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: nitric oxide; haem oxygenase; antiapoptosis; oxidative stress; tumour growth
                                           
Haem oxygenase (HO) is the rate-limiting enzyme in haem
degradation; this reaction produces biliverdin, which is subse-
quently converted to bilirubin by biliverdin reductase in biological
systems (Tenhunen et al, 1968). Haem oxygenase -2 (HO-2) is the
constitutive isoform of HO and is highly expressed in testis and
brain under physiological conditions (Manies, 1997). Haem
oxygenase -1 (HO-1), the inducible isoform of HO, also known
as heat shock protein 32 (HSP32), is found at low levels in most
mammalian tissues, but it is constitutively expressed in liver and
spleen and is upregulated by its substrate haem (Tenhunen et al,
1970) and various stress-inducing stimuli such as UV light (Keyse
and Tyrrell, 1989), heavy metals (Mitani et al, 1993), heat shock
(Shibahara et al, 1987), hypoxia (Motterlini et al, 2000), and nitric
oxide (NO) (Kim et al, 1995; Foresti and Motterlini, 1999; Bouton
and Demple, 2000). Induction of HO-1 is suggested to have a
cytoprotective effect against oxidative injury (Dennery et al, 1997;
Suttner et al, 1999), because some bile pigments formed via HO
have been shown to behave as antioxidants (Minetti et al, 1998;
Dore et al, 1999).
We previously showed in an experimental solid tumour that NO
produced in excess in the local area surrounding tumour cells
seemed to sustain rapid tumour growth (Doi et al, 1996). It has
been reported, however, that a particularly high output of NO from
inducible nitric oxide synthase (iNOS) is potentially cytotoxic for
various tumour cells (Bastian et al, 1994). In this context, our
earlier study indicated that HO-1 is upregulated by NO produced
by iNOS in an experimental solid tumour (Doi et al, 1999). Haem
oxygenase-1 may provide important protection for tumour cells, so
that tumour cell growth is sustained by HO-1 even under oxidative
stress induced by excessive NO. In fact, we found that tumour
growth was remarkably suppressed by the administration of zinc
protoporphyrin IX (ZnPP IX, an HO-1 inhibitor) to tumour-
bearing rats (Doi et al, 1999). However, these cytoprotective
mechanisms of HO-1 remain to be identified.
It is intriguing that overexpression of HO-1 protects endothelial
cells from apoptosis induced by the host’s rejection reaction in a
rodent cardiac transplantation model (Hancock et al, 1998; Soares
et al, 1998). In the present study, we investigated the mechanism of
HO-1 cytoprotection of tumour cells, with a focus on the
antiapoptotic potential of HO-1, which may contribute in a critical
way to tumour growth in vivo.
MATERIALS AND METHODS
Animals and implantation of AH136B tumour
AH136B tumour (rat hepatoma) cells were implanted subcuta-
neously (s.c.) in a dorsal site on the foot of male Donryu rats
weighing 160–180g (SLC, Inc., Shizuoka, Japan) with an inoculum
size of 1 10
7 cells per injection site as described previously (Doi
et al, 1996). Tumours were allowed to grow for 14 days and usually
reached a diameter of 10–15mm. We used the tumours with about
10mm in diameter for the present studies. The solid tumour did
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animals: no motor dysfunctions of the limb including paralytic
and shuffling gaits and no apparent symptoms of peripheral
circulatory failure in the distal area of the tumour implantation site
(nor necrosis) were observed during this experiment. All animal
experiments were carried out with approval by the Ethical
Committee at the Center for Animal Resources and Development,
Kumamoto University, which met the standard required by the
United Kingdom Co-ordinating Committee on Cancer Research
(UKCCCR) guidelines (Workman et al, 1998).
Treatment of AH136B solid tumour with ZnPP IX in vivo
For the treatment of AH136B tumour in vivo, 500mgkg
 1 ZnPP IX
(Sigma-Aldrich Fine Chemicals, St Louis, MO, USA) or copper
protoporphyrin IX (CuPP IX, Frontier Scientific Inc., Logan, UT,
USA) (500mg of each in 1ml of 10% dimethyl sulphoxide (DMSO)
in 0.01 M NaOH) was injected intra-arterially (i.a.) into solid
tumour via the common iliac artery that is mainly feeding the
tumour, so that effective delivery of these compounds is achieved.
Solid tumours were obtained 24h after injection and were stored at
 801C until use for terminal deoxynucleotidyl transferase (TdT)-
mediated dUTP-biotin nick end-labelling (TUNEL) staining and
for analyses of HO-1 and HSP70.
Analysis for apoptosis and viability of AH136B cells
treated with HO inhibitors in vitro
AH136B tumour cells, at 5 10
5 cells per well of a six-well
polystyrene plate (Falcon, Becton Dickinson Labware, Lincoln
Park, NJ, USA), were incubated with various concentrations of the
HO inhibitors ZnPP IX and tin protoporphyrin IX (SnPP IX,
Frontier Scientific) (Drummond and Kappas, 1981) in Dulbecco’s
minimum essential medium (Invitrogen Corp., Carlsbad, CA, USA)
supplemented with 10% (vv
 1) fetal bovine serum and 0.5%
nonessential amino acids (Invitrogen). After 24h of culture, the
cells were subjected to the cell viability and apoptosis assays of
TUNEL staining and caspase-3 activity determination. Similarly,
the cells were treated with CuPP IX, which has no direct inhibitory
effect on HO activity in vivo (Drummond and Kappas, 1981) and is
a poor HO inhibitor in vitro (Zakhary et al, 1996). Also, the effects
of ZnPP IX on cultured cells were examined in the presence of
bilirubin (Wako Pure Chemical Co., Ltd, Osaka, Japan) or caspase-
3 inhibitor (acetyl-Asp-Met-Gln-Asp-CHO; Peptide Institute, Inc.,
Osaka, Japan). Cell viability was determined via the trypan blue
dye exclusion assay (Kimura et al, 1990). Analyses for TUNEL
staining and caspase-3 activity were performed as described below.
Effect of NO on expression of HO-1 and HSP in AH136B
tumours
Tumour-bearing rats were administered either N
o-nitro-L-arginine
methyl ester (L-NAME, Sigma-Aldrich Fine Chemicals) or S-
methylisothiourea sulphate (SMT, Wako Pure Chemical Co., Ltd)
in 0.2ml of 0.9% NaCl solution, given intraperitoneally (i.p.) at a
dose of 6mgkg
 1 per day for 5 days, beginning 9 days after
tumour implantation. Solid tumour tissues were obtained 1 day
after the last injection of NOS inhibitor and were stored at  801C
until use for HO-1 and HSP70 Western blotting. The effect of
ischaemic stress on the expression of HSP70 protein in solid
tumour was also examined. Briefly, on day 14 after tumour
implantation, solid tumours were resected for Western blot
analysis at different times after initiation of surgical occlusion of
the common iliac artery, which serves the tumour-feeding artery of
the tumour-implanted side. In addition, the effect of NO on the
expression of HO-1 and HSP70 was examined with the use of
AH136B cells in culture treated with the NO donors S-nitroso-N-
acetyl penicillamine (SNAP, Dojindo Laboratories, Kumamoto,
Japan) and propylamine NONOate (CH3N[N(O)-
NO]
 (CH2)3NH2
+CH3) (P-NONOate, Dojindo Laboratories). Wes-
tern blotting was used to analyse the levels of HO-1 and HSP70
proteins in lysate of the AH136B cells, after a 6-h incubation with
the NO donors.
TUNEL assay
Suspensions of cultured AH136B cells, treated with various
compounds as just described, were spotted onto glass microscope
slides and were dried at room temperature, followed by TUNEL
staining. For the analysis of solid tumour tissues, 6-mm-thick
frozen tissue sections were prepared with a cryostat and were air-
dried overnight. Apoptotic cells were detected via the TUNEL
method by using an apoptosis detection kit (TACS; Trevigen Inc.,
Gaithersburg, MD, USA) (Ikebe et al, 2000).
Caspase-3 assay of AH136B tumour cells
Caspase-3 activity in AH136B tumour cells was measured as
described previously (Enari et al, 1996). Briefly, lysates of AH136B
cells, having had treatment with various compounds or no
treatment, were incubated for 30min at 371C with 1mM MOCAc-
Asp-Glu-Val-Asp-Ala-Pro-Lys(Dnp)-NH2 fluorescent substrate
(Peptide Institute). Ac-DMQD-CHO, caspase-3 inhibitor (Peptide
Institute), was added to the reaction mixture at a concentration of
10mM. Caspase-like amidolytic activity for the peptidyl substrate
was measured fluorometrically and caspase activity was deter-
mined by subtracting the fluorescence values obtained in the
presence of inhibitor.
Measurement of HO activity in tumour cells and solid
tumours
Haem oxygenase activity in AH136B tumour cells and solid
tumours was quantified with use of the microsomal fraction
extracted from each sample according to our previously described
method (Doi et al, 1999). The reaction mixture for the measure-
ment of HO activity was composed of microsomal protein (1mg),
cytosolic fraction of rat liver (1mg protein) as a source of
biliverdin reductase, 33mM hemin, and 333mM NADPH of 1ml of
90mM potassium phosphate buffer, pH 7.4. The bilirubin formed
in the reaction (15min at 371C) was quantified spectroscopically
(Doi et al, 1999).
In vivo microdialysis
This technique was employed to assess the NO production in
tumour tissue in vivo (Ohta et al, 1994). A microdialysis probe
(straight type, outer diameter 220mm, length 5mm, cellulose
membrane, cutoff 50000Da; Eicom Corp., Kyoto, Japan) was
implanted in the solid tumour, and was perfused using a
microsyringe pump (ESP-64, Eicom Corp.). After an equilibration
period (1h), dialysate was collected in polyethylene tubes for
15min, followed by measurement of NO2
  and NO3
  by using an
NOx analyzer (ENO-10, Eicom Corp.) (Akaike et al, 1997).
Measurement of tumour blood flow
Tumour blood flow was measured before and 1, 3, 6, 12, and 24h
after injection of 500mgkg
 1 ZnPP IX via the tumour-feeding
artery or after i.p. injection of 6mgkg
 1 L-NAME. A laser Doppler
flowmeter (Laser Flow Meter, ALF21, Advance, Tokyo, Japan) was
used for measurement of the tumour blood flow via a probe needle
placed into the tumour tissue as described earlier (Ikebe et al,
2000).
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Lysates of AH136B cells treated or untreated with various reagents
were prepared as described previously (Doi et al, 1999). HSP70 was
induced by a standard heat shock treatment at 421C for 30min
followed by a 6-h incubation under normal culture conditions as
described above. The supernatant of homogenates (10000g,
30min) of tumour tissues treated with ZnPP IX (500mgkg
 1,
i.a.), NOS inhibitors, or vehicle was subjected to Western blot
analysis for HSP70. The microsomal fraction obtained by
ultracentrifugation was used for the HO-1 analysis. Total protein
(25mg each) in cell lysates or tissue homogenates was used for the
Western blotting with a monoclonal antibody to HSP70 (SPA-810,
Stressgen, Victoria, BC, Canada), which specifically recognises the
inducible but not the constitutive isoforms of the HSP70 family in
mammals, or a polyclonal antibody to HO-1 (OSA-150, Stressgen).
The protein band that reacted immunologically with the antibody
was visualised by using the ECL system (Amersham International
plc, Buck, UK).
Statistical analysis
Data are shown as means7s.e. Statistical difference was analysed
by the use of the two-tailed unpaired t-test and by ANOVA. A P-
value of o0.05 was considered statistically significant.
RESULTS
Zinc protoporphyrin IX -induced apoptosis and inhibition
of HO activity in AH136B solid tumours
Strong staining of TUNEL-positive cells was detected in ZnPP IX-
treated tumour tissue (Figure 1A, B); however, the vehicle (control)
(Figure 1A, A) and the CuPP IX-treated (Figure 1A, C) tumour
tissues showed only negligible staining. Morphometric analysis of
TUNEL-positive cells in AH136B solid tumours revealed a
significantly higher number of TUNEL-positive cells in the ZnPP
IX-treated group (21076mm
 2) compared with the control group
(1472mm
 2) and the CuPP IX-treated group (2074mm
 2)
(Figure 1B).
A significant, although not complete, inhibition of HO activity in
solid tumour tissue was obtained by ZnPP IX treatment
(Figure 1C). The CuPP IX-treated group showed almost the same
level of HO activity as the control group. These results suggest that
ZnPP IX-induced apoptosis in AH136B solid tumour is mediated
through the inhibition of HO activity by ZnPP IX.
Zinc protoporphyrin IX-induced apoptosis and inhibition
of HO activity in AH136B cells in culture
Cultured AH136B cells were incubated for 24h with indicated
concentrations of ZnPP IX (with or without a caspase-3 inhibitor)
or SnPP IX, or with 100mM CuPP IX (Figure 2). The number of
TUNEL-positive cells in the CuPP IX-treated group (8.171.3%)
was comparable to that of the control group (6.673.8%). In
contrast, 1mM and higher concentrations of ZnPP IX potentiated
the induction of apoptosis in AH136B cells in a concentration-
dependent manner (46.7% at 100mM ZnPP) (Figure 2A). A similar
trend for the induction of apoptosis was observed with another HO
inhibitor, SnPP IX (Figure 2B). The ZnPP IX-induced apoptosis
was completely inhibited by simultaneous incubation with a
specific caspase-3 inhibitor (at 1 or 10mM). The viability of tumour
cells was inversely decreased in a concentration-dependent
manner after ZnPP IX treatment (inset in Figure 2A, B).
Figure 2C shows representative TUNEL staining of control and
ZnPP IX-treated tumour cells (100mM ZnPP IX), illustrating a
considerable number of TUNEL-positive cells in the ZnPP IX-
treated group compared with the control staining.
Zinc protoporphyrin IX treatment resulted in a remarkable
reduction of HO activity in the cells (Figure 3A), which correlated
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Figure 1 Apoptosis induction and change in HO activity after treatment with ZnPP IX of AH136B solid. Apoptosis (A, B) and HO activity (C) were
assessed on day 14 after tumour implantation. Each specimen was analysed via TUNEL staining 24h after treatment with vehicle (the control) (A, a), with
ZnPP IX (500mgkg
 1 i.a.) (A, b), or with CuPP IX (500mgkg
 1 i.a.) (A, c). Quantitative analysis of TUNEL-positive cells in each specimen is shown (B).
TUNEL-positive cells were counted in four different fields of magnification at  100 per sample, and then the number of positive cells per mm
2 was
calculated. Haem oxygenase activity of the solid tumour was measured after treatment in the same manner as in the TUNEL analysis (C). *Po0.05,
**Po0.01 vs control (n¼3 for each group). Data are means7s.e. See text for details.
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(Figure 2). Copper protoporphyrin IX, which showed no appreci-
able apoptotic effect, also did not affect cellular HO activity
(Figure 3A). In addition, caspase-3 activity in AH136B cells was
greatly increased after 24h of incubation with 100mM ZnPP IX, and
this increase was totally nullified by simultaneous incubation with
caspase-3 inhibitor at concentrations of 1 and 10mM (Figure 3B).
These results are consistent with the finding from the in vivo solid
tumour study and indicate again that pharmacological blockade of
HO activity induces apoptotic change of the AH136B tumour cells.
Protective effect of bilirubin against ZnPP IX-induced
apoptosis of AH136B cells
We further examined the effect of bilirubin, which is biologically
derived from biliverdin, an important enzymatic reaction product
of HO (Figure 4). There was a trend toward inhibition of ZnPP IX-
induced apoptosis even at 0.001mM bilirubin, although it was not
statistically significant. Addition of 0.01mM or higher concentra-
tions of bilirubin caused a marked reduction in the number of
TUNEL-positive cells. This suppressive effect of bilirubin on ZnPP
IX-induced apoptosis of AH136B cells was not truly dose
dependent, however, and one-third of the TUNEL-positive cells
remained unaffected at the highest concentration of bilirubin
(100mM).
Effect of ZnPP IX treatment on blood flow and NO
production in AH136B solid tumours
Carbon monoxide (CO) generated by HO has been demonstrated
to be a potential endogenous modulator of vascular tone in the
liver (Suematsu et al, 1994). Hence, we examined whether ZnPP IX
treatment modulated blood flow in this solid tumour through the
inhibition of CO biosynthesis (Figure 5). Tumour blood flow was
not affected by ZnPP IX in this model, although it was significantly
decreased 1, 3, 6, and 12h after administration of L-NAME.
Moreover, ZnPP IX did not appreciably affect NO production in
AH136B solid tumours, as evidenced by the microdialysis
technique to analyse the amount of NO2
  and NO3
  in situ
generated in the dialysate of the tumour tissues: 3.571.1 and
3.271.4mM of NO2
  and NO3
  were generated for 15min in 10ml
dialysates of the tumour tissues before and 24h after ZnPP IX
treatment, respectively (n¼5 for each group; P¼0.67). No
appreciable suppression for NO production was observed at any
time points (1, 2, 3, 6, and 12h) after ZnPP IX administration (data
not shown).
Expression of HSP70 and HO-1 proteins in AH136B cells
and solid tumours
Western blotting was performed to analyse the expression of HO-1
protein and another important HSP, HSP70, in AH136B tumour
cells and solid tumour tissues (Figure 6). Not only AH136B cells in
culture but also AH136B solid tumours grown in vivo show
constitutive expression of HSP70 and HO-1 proteins without any
particular stimulation. The levels of expression of both of these
proteins were strongly upregulated by heat shock treatment. The
expression of HO-1 was also greatly enhanced by NO generated
exogenously from SNAP or P-NONOate added to the culture of the
AH136B tumour cells (Figure 6A, upper panel), whereas the same
treatment produced no measurable change in HSP70 expression
(Figure 6A, lower panel). Also, ZnPP IX treatment of the cultured
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Figure 2 Zinc protoporphyrin IX-induced apoptosis of AH136B cells in vitro. AH136B cells were incubated for 24h with indicated concentrations of
ZnPP IX, with or without caspase-3 inhibitor (A) or SnPP IX (B), or with 100mM CuPP IX. (A, B) TUNEL-positive cells were counted in four different fields
of magnification at  100 per sample, and then the percentage of positive cells was calculated. *Po0.05 vs control (n¼3 for each group). Cell viability after
the same treatment is shown in the inset. *Po 0.05, **Po0.01 vs control (n¼4 for each group). Data are means7s.e. (C) Representative TUNEL staining
of control and ZnPP IX-treated tumour cells. See text for details.
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Figure 4 Protective effect of bilirubin against ZnPP IX-induced apoptosis
of AH136B cells. AH136B cells were incubated for 24h with 100mM ZnPP
IX in the presence or absence of indicated concentrations of bilirubin.
TUNEL-positive cells were counted in four different fields of magnification
at  100 per sample, and then the percentage of positive cells was
calculated. *Po0.05 vs ZnPP IX alone (n¼3 for each group). Data are
means7s.e. See text for details.
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Figure 5 Tumour blood flow after ZnPP IX or L-NAME treatment.
Tumour blood flow was measured in AH136B solid tumour on day 14 after
tumour implantation. At the indicated times after injection of 500mgkg
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 1 L-NAME (i.p.), a laser Doppler flowmeter and a
probe needle were used to measure blood flow. Relative changes in
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25min). **Po0.01 by ANOVA between the groups (n¼3 for each time
point). Data are means7s.e. See text for details.
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Figure 6 Western blot analysis of HSP70 and HO-1 proteins in
AH136B cells and solid tumours. (A) Cells were incubated with SNAP (10
or 100mM), P-NONOate (10 or 100mM), or ZnPP IX (100mM) for 6h or,
as a positive control, were treated by heat at 421C for 30min, followed by
incubation at 371C for 6h. (B) AH136B solid tumours were treated with
0.9% NaCl solution (control), ZnPP IX (500mgkg
 1 i.a.), L-NAME
(6mgkg
 1day
 1 for 5 days i.p.), or SMT (6mgkg
 1day
 1 for 5 days
i.p.). (C) Solid tumours were resected at 24 or 48h after initiation of
surgical occlusion of the common iliac artery, which serves the tumour-
feeding artery of the tumour-implanted side. Control rats were treated by
sham operation. Then, expression of HSP70 and HO-1 proteins was
detected by Western blotting by using a monoclonal antibody to
mammalian inducible HSP70 or a polyclonal antibody to rat HO-1. Each
data point shown represents three independent experiments. See text for
details.
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panel). Similarly, ZnPP IX administration to solid tumour tissues
did not influence HO-1 or HSP70 expression in vivo (Figure 6B),
suggesting no compensatory regulation of HO-1 and HSP70.
Haem oxygenase-1 expression in AH136B tumour tissues in vivo
was strongly attenuated by treatment with L-NAME or SMT
(Figure 6B, upper panel), which is consistent with the in vitro
result of strong upregulation of HO-1 in AH136B tumour cells
induced by NO. In contrast, the level of HSP70 expression was
increased by the same NOS inhibitor treatment (Figure 6B, lower
panel). This upregulation of HSP70 by NOS inhibitors was possibly
caused by hypoxic stress of the solid tumour tissues produced by
blockade of NO biosynthesis. The same HSP70 upregulation
occurred after an ischaemic insult caused by occlusion of the
tumour-feeding artery (Figure 6C). These data indicate that HO-1
expression was regulated mainly by NO generated endogenously in
the solid tumour tissue, whereas HSP70 expression was modulated
through a separate mechanism, possibly dependent on a hypoxic
cellular signalling pathway of the tumour cells.
DISCUSSION
In the present study, we clearly demonstrate that HO-1 induced by
NO had a potent antiapoptotic function in an experimental
AH136B solid tumour in rats. Earlier studies suggested a
cytoprotective effect of HO-1, that is, inhibition of apoptosis in
transplant injury during organ rejection and of TNF-a-induced
apoptosis in fibroblasts (Hancock et al, 1998; Soares et al, 1998;
Petrache et al, 2000). Here, we found that ZnPP IX induced the
apoptosis of AH136B cells both in vivo and in vitro through
inhibition of HO-1 activity, and HO-1 activity was upregulated by
NO generated in the tumour tissues. It was recently reported that
ZnPP IX had a direct cytotoxic effect through apoptosis induction,
regardless of HO inhibition (Lutton et al, 1997). Another potent
HO inhibitor is, however, shown not to have such a direct
cytotoxic (apoptotic) effect (Yang et al, 2001). In our study, not
only ZnPP IX but also SnPP IX, which inhibits HO specifically
without direct cytotoxic action, showed potent apoptosis-inducing
potential in AH136B tumour cells. In addition, ZnPP IX treatment
of the rats did not affect the blood flow in the tumour tissue
(Figure 5), suggesting that ZnPP IX does not have a significant
inhibitory effect at least on the soluble guanylate cyclase activity as
seen in blood flow (via NO-cGMP pathway), which is a major
inducer for vasorelaxation. It is thus reasonable to conclude that
the HO-1 expressed by the tumour cells may have a cytoprotective
function, so that the solid tumour can grow effectively during the
oxidative stress that occurs as the tumour grows.
To further confirm the antiapoptotic activity of HO-1, we
performed a separate experiment by using a small interfering RNA
(siRNA) to suppress specifically the expression of HO-1.
Specifically, endogenous HO-1 mRNA was targeted in cultured
SW480 cells, a cell line of human colon adenocarcinoma, by
transfecting a 21-nucleotide duplex siRNA derived from the HO-1
nucleotide sequence according to the method reported recently
(Elbashir et al, 2001). Small interfering RNA-treated SW 480 cells
underwent a significant apoptotic change, which was almost
comparable to the effect of ZnPP IX added to the cell culture (data
not shown). These data indicate a clear cause and effect relation for
the HO-1-mediated antiapoptotic effect.
It is of considerable importance that bilirubin, which is
converted from biliverdin, a product of HO, significantly decreased
the number of TUNEL-positive AH136B cells treated with ZnPP IX.
Bilirubin appears to be one of the most abundant endogenous
antioxidants in mammalian tissues and accounts for most of the
antioxidant activity in human serum (Minetti et al, 1998). Bilirubin
displayed potent scavenging activity against various oxidants
including superoxide, peroxyl radical, and peroxynitrite (Minetti
et al, 1998; Dore et al, 1999). More importantly, a neuroprotective
effect of bilirubin derived from HO-2 has been shown for hydrogen
peroxide-induced cytotoxicity in cultured rat primary neuronal
cells (Dore et al, 1999). Since oxidative stress is suggested to be a
potential mediator of apoptosis induction (Buttke and Sandstrom,
1994), it is reasonable that the antioxidant activity of bilirubin just
mentioned may antagonise the apoptosis elicited by HO inhibitor
treatment in AH136B tumours.
However, bilirubin is also reputed to be a potentially toxic agent,
particularly when it accumulates in the serum of neonates and
causes jaundice. At high concentrations, bilirubin is deposited in
selected brain regions and produces neurotoxicity associated with
kernicterus (Gourley, 1997). In our present study, no clearly dose-
dependent inhibitory effect of bilirubin on ZnPP IX-induced
apoptosis of AH136B cells was observed with bilirubin concentra-
tions at more than 0.1mM. This incomplete inhibition of apoptosis
by bilirubin may be attributed to the cytotoxic effect of bilirubin
itself rather than its antioxidant activity.
Another explanation for the saturated antiapoptotic effect of
bilirubin is that CO, which is a catalytic by-product of HO-1
activity, may be involved in the cytoprotective mechanism of HO-
1. In fact, Choi’s group demonstrated that TNF-a-induced
apoptosis in cultured fibroblasts was inhibited by CO exposure
(Petrache et al, 2000). Moreover, a low concentration of CO can
provide protection against hyperoxic lung injury in vivo (Otterbein
et al, 1999).
CO has been suggested to function as a neurotransmitter and
also as an endogenous modulator of vascular perfusion in the liver
through a mechanism analogous to that of NO (Suematsu et al,
1994). Zinc protoporphyrin IX was previously shown to reduce the
tumour blood flow relatively selectively via mechanisms unrelated
to HO inhibition (Tozer et al, 1998). It is important to confirm the
lack of NOS inhibition by ZnPP IX, because NO has a biological
effect very similar to HO-1 in terms of sustaining the solid tumour
growth (Doi et al, 1996) as well as antioxidant effect. However,
ZnPP IX affected neither tumour blood flow nor NO biosynthesis
in the AH136B solid tumour tissue; whereas, tumour blood flow
was significantly decreased by treatment with an NOS inhibitor (L-
NAME). These data suggest that NO rather than CO derived from
HO may be the dominant modulator of tumour blood flow, at least
in this solid tumour model.
Although several reports have shown a cytoprotective effect of
HO-1 (Dennery et al, 1997; Suttner et al, 1999), contradictory
effects of the biological consequences of overexpression of HO-1
have also been reported. Specifically, a study by Suttner and
Dennery (1999) indicated that overexpression of HO-1 could
exacerbate the oxidative stress of cells, and they revealed a critical
role of reactive iron (ferric iron, Fe
2+) released during HO-catalytic
decomposition of the porphyrin ring of haem in determining the
consequence of HO expression.
In our own study, we assumed that some other cytoprotective
system may occur to compensate for such a disadvantage of HO-1
induction in our experimental solid tumour. HSP70, which is one
of the most important HSPs ubiquitously distributed in mamma-
lian systems (Schlesinger, 1990; Xu et al, 1997), was expressed by
AH136B cells and solid tumours. However, although HSP70 has
been reported to be induced by NO exposure (Xu et al, 1997), our
present analysis of HSP70 with NO donors and NOS inhibitors in
vitro and in vivo showed that NO does not participate in HSP70
upregulation in AH136B cells. Thus, we suggest that HSP70
expression in AH136B tumours may be positively regulated by
ischaemia or hypoxia through a mechanism different from HO-1
induction involving NO.
AH136B experimental solid tumour tissues produce a high
amount of NO, which seems to sustain rapid tumour growth, as we
reported previously (Doi et al, 1996). NO mediates angiogenesis
and enhanced vascular permeability in solid tumour (Jenkins et al,
1995; Wu et al, 1998), and is implicated in the maintenance of
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In addition, it has been reported that NO inhibits apoptosis and its
mechanism appears to be via inhibition of the caspase protease
cascade (Mannick et al, 1994; Ogura et al, 1998). However, no
significant modification of NO production was observed with
ZnPP IX treatment, as determined by microdialysis-based NO2
 
and NO3
  measurement in our experimental model, indicating that
the apoptotic change in the AH136B solid tumours after ZnPP IX
treatment depended mostly on the specific suppression of HO
activity.
In conclusion, our current study indicates that HO-1 may
function as an antiapoptotic defense system for the tumour, and it
may also have important protective and beneficial effects for
tumour cells against oxidative stress occurring during rapid
growth of solid tumour in vivo. Thus, HO-1 may become a
potential target for cancer chemotherapeutic agents, particularly in
combinations with conventional agents. The present study
warrants further investigation to develop new tactics for anti-
tumour treatment with the use of HO inhibitors such as ZnPP IX
or its polymer-conjugated derivatives with improved pharmaco-
logical properties (Sahoo et al, 2002).
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